Selected Literature Peer-reviewed publications cited in this overview [1] Sikiric P, et al
Current FDA Status of Compounded GLP-1s (Shortage List Changes) As of early 2026, the FDA status of compounded GLP-1 medications remains a dynamic and closely watched issue
Existing drugs such as GC therapy, which upregulates CD163, anti-diabetic drug, pioglitazone, which upregulates CD36, and a kinase inhibitor, imatinib, which upregulates SRBI, may be evaluated for potential in regulating the clearance of hemolysis products at the receptor level (Schaer et al., 2002
, Professor Akiko Iwasaki has a different theory
Research Mechanism (Mechanism of Action) NNMT normally catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA)